Analysis of Adagrasib indications: How to delay the recurrence of KRAS G12C mutated lung cancer

Adagrasib is an innovative targeted drug that has attracted much attention in the field of oncology in recent years. As one of the world's first approved oral inhibitors targeting the KRAS G12C mutation, it provides a new treatment idea for the KRAS gene, which has long been considered "undruggable" in the past. With the continuous advancement of relevant research, adagrasib has gradually shown an important position in clinical practice and the global market. This article will combine the latest international data to conduct an in-depth analysis from the aspects of indications, usage and dosage, mechanism of action, clinical efficacy, price status, etc., and conduct an extended discussion on how to delay the recurrence of KRAS G12C mutated lung cancer based on current hot trends.

xa0

Analysis of indications of adagrasib

KRAS gene mutation is one of the most common driver mutations in non-small cell lung cancer (NSCLC), accounting for approximately 25%, of which KRAS G12C mutation is a specific subtype. In the past, due to the complex structure of KRAS protein, drug research and development has been repeatedly frustrated, and it has long been called an "undruggable target." The emergence of Adagrazeb changed this situation. According to international guidelines and drug inserts, adagrasib is mainly used to treat adult patients with locally advanced or metastatic NSCLC who carry KRAS G12C mutations and have received at least one previous systemic therapy. This means that it is mainly suitable for patients who have failed previous first- or second-line treatments, bringing new hope to clinical practice.

In recent years, the U.S. FDA and European EMA have accelerated the approval of KRAS inhibitors, showing the regulatory attention they attach to this innovative target. Since it has not yet been approved for marketing in mainland China, relevant patients can only obtain it through cross-border channels.

Usage and dose adjustment of adagrasiib

Before taking the drug, patients must undergo molecular testing to confirm the presence of the KRAS G12C mutation. This test can be done through a tumor tissue biopsy or a liquid biopsy (plasma). In cases where no mutations are found in plasma testing, it is still necessary to go back to tissue testing to avoid false negatives.

The recommended dose is 600 mg orally twice daily, for a total dose of 1200 mg/day. The method of taking the medicine is flexible and can be taken with food or on an empty stomach, but it needs to be kept for a fixed time to maintain the stability of the drug concentration in the body.

During the actual treatment process, some patients may need to adjust the dose due to adverse reactions. Doctors usually reduce the dose to 400 mg twice daily or even to 600 mg once daily, depending on tolerance. If the patient cannot tolerate the lowest dose, the drug needs to be discontinued. Reasonable dose management is a key link to ensure efficacy and safety.

Innovation in the mechanism of action of adagrasib

Adagrasiib is a selective, irreversibleKRAS G12C inhibitor. Its mechanism of action is to form a covalent bond with the cysteine u200bu200bresidue of the KRAS G12C mutant protein, thereby locking KRAS in an inactive state. This mechanism can effectively block the continued activation of the downstream MAPK pathway and PI3K pathway, thereby inhibiting tumor cell proliferation and survival.

Unlike traditional chemotherapy, adagrasib does not kill normal cells on a large scale, but precisely targets mutant proteins, so side effects are relatively controllable. In addition, it has a long half-life in the body and has sustained inhibitionThe advantage of KRAS activity can reduce the risk of drug resistance.

xa0

xa0

Clinical efficacy and research progress

In multiple international clinical studies, adagrasib has shown encouraging efficacy. Some patients experienced significant tumor shrinkage and even longer disease control after use. Especially in patients with advanced NSCLC who have failed previous treatments, the objective response rate and disease control rate of adagrasib exceeded expectations.

It is worth mentioning that researchers are also exploring the potential of combining adagrasib with other therapies. For example, combined use with PD-1/PD-L1 immune checkpoint inhibitors, or combined treatment with EGFR inhibitors, SHP2 inhibitors, etc., all show certain prospects. Combination therapy is expected to break through the bottleneck of single-drug resistance and bring long-term benefits to more patients.

Adverse reactions and safety considerations

Although adagrasib is highly targeted, it may still cause some adverse events. Common symptoms include nausea, vomiting, diarrhea, fatigue, elevated liver function indicators, and electrolyte imbalance. Some patients may develop laboratory abnormalities of grade 3 or above, which requires close monitoring and timely dose adjustment. Clinically, doctors will develop an individualized treatment plan based on the patient's age, liver and kidney function, and concomitant medication. Overall, adagrasiib is well manageable, and most adverse reactions can be controlled through supportive treatment and dose adjustment.

Comparison of global prices and original generic drugs

Adagrasib was developed by Mirati Therapeutics in the United States and was later acquired by Bristol-Myers Squibb (BMS). The specification of the original drug in the United States is 200mg*180 tablets, and the price is as high as hundreds of thousands of yuan. It is a typical representative of high-end innovative drugs. Due to patent protection, there is currently no officially launched version in China.

However, generic drugs are already available in some Southeast Asian countries (such as Laos). Taking the Lao version of Lucius Pharmaceuticals as an example, the price of 200mg*90 tablets is about 3,000 yuan, with a huge price gap. Although the ingredients of this type of generic drugs are basically the same, their production standards and quality supervision systems may be different from those in Europe and the United States, so patients should be cautious when choosing them.

From a global market perspective, as more companies join the research and development of KRAS inhibitors, prices are expected to gradually decline in the future, especially competition from generic drugs will drive changes in the market structure.

xa0

xa0

Combined therapy and resistance mechanism of adagrasiib

The problem of drug resistance has always been one of the main challenges in targeted tumor therapy. For adagrasib, although it can effectively inhibit KRAS G12C mutation, tumor cells may reactivate signaling pathways through other ways, leading to the occurrence of drug resistance. For example, other mutations in the KRAS gene, KRAS copy number amplification, and bypass activation of downstream pathways such as PI3K and MAPK are all known resistance mechanisms.

In order to delay drug resistance, researchers have proposed a variety of combination treatment ideas:

Adagrasib + immunotherapy: By combining with immune checkpoint inhibitors, the anti-tumor immune response can be enhanced, and some clinical data have shown synergistic effects.

Adagrasib + EGFR inhibitor: In some patients with KRAS mutations and active EGFR signaling, this combination is expected to block multiple pathways.

adagrasib + SHP2 inhibitor: SHP2's critical role in the KRAS pathway makes it an important combination target to reduce the chance of bypassing activation.

Future research will focus on how to delay or overcome drug resistance through combination strategies, thereby extending patient survival time and improving quality of life.

Future Outlook

Adagrasib is not only the hope for KRAS G12C mutation patientsit also represents a milestone in the development of cancer drugs. With the advancement of more combination programs and cross-cancer research, its application prospects are extremely broad. In the future, how to delay drug resistance, optimize dosing methods and expand indications will become the focus of both academia and industry.

For domestic patients, the introduction of adagrasib will be an important step in a new era of precision treatment. As the medical insurance negotiation mechanism gradually matures, its prices are expected to become more affordable in the future and truly benefit the majority of patients.

Reference links:

https://www.krazati.com/

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-krazati

https://www.nejm.org/

https://www.bms.com/